Gilead’s Quad Pill Raises Kidney Questions, FDA Says - Bloomberg

The therapy mixes Gilead’s two-drug medicine Truvada, approved in 2004, with Bristol-Myers Squibb Co. (BMY)’s Sustiva. Quad contains four Gilead compounds in a single pill that patients take once a day. An FDA review of studies funded by ...

FDA report on Gilead's Quad focuses on kidney safety - msnbc.com

Most of the company's current drug sales, which totaled $8.1 billion last year, come from Atripla, a once-daily pill that combines Truvada with Bristol-Myers Squibb's Sustiva. Truvada consists of Gilead's older HIV drugs Emtriva and Viread.

HIV Drug Maker Gilead Sciences Scores Two Wins - Minyanville

Like Quad, Atripla is a once-daily pill combining medicines -- two Gilead drugs and Bristol-Myers Squibb’s (BMY) Sustiva. The neurological side effects of Atripla are attributed to Sustiva, which is not included in Gilead’s Quad. Quad is a ...

4 Large Cap Dividend Stocks With Strong Profits That Analysts Rate As Buy - Seekingalpha.com

The company's principal products also comprise SUSTIVA for the treatment of HIV; BARACLUDE, an inhibitor of hepatitis B virus; ERBITUX to target and block the epidermal growth factor receptor; SPRYCEL for treatment of chronic myeloid leukemia in adults ...

BUYINS.NET: Market Maker Surveillance Report. MS, T, JPM, BMY, … - TMCnet

The companys principal products also comprise SUSTIVA for the treatment of HIV; BARACLUDE, an inhibitor of hepatitis B virus; ERBITUX to target and block the epidermal growth factor receptor; SPRYCEL for treatment of chronic myeloid leukemia in ...

Op-ed: Riding Is Like Choosing to Live - Advocate

My T-cell count was two. And my viral load was off the chart. My doctor immediately put me on a cocktail of Sustiva and Combivir. I spent that next month in the hospital. Five years or so later he changed my cocktail regimen to Atripla ...

The Global Antivirals Market Expected To Reach $30 Billion By 2017 - OfficialWire

Some major patent expiries are expected during the forecast period, such as for Sustiva, Combivir, Tenofovir, Telbivudine, Tamiflu and Relenza. The patent expiries of these blockbuster drugs will trigger generic competition in the antivirals market ...